hustbelogehy1857.blogspot.com
GenVec, Inc. (Nasdaq: GNVC) is a clinical stage biopharmaceutical company developing and working to commercializeinnovative gene-basex therapeutics to treat serious and life-threatening including cancer, heart disease and diseases of the eye. We have four producft candidates in clinical developmentas follows: - TNFerade is our lead producr candidate, a novel therapy with a unique mechanism of actiohn for use by multi-disciplinary oncology currently in Phase 2 trials in locallyy advanced pancreatic cancer, non-metasticv esophageal cancer and rectal cancer.
- BioBYPASa Positive data presented froma randomized, controlled Phase 2 study in 71 patientsx with severe heart disease and no treatment options. We expect to begin a placebo-controlled Phase 2B trial with our Cordis Corporation, in the fourth quarter of 2004 to study the clinicapl benefit of BIOBYPASS delivered by the NOGASTAR mapping and Myostatr injection catheter system. - AdPEDF Patient enrollment completed in a dose escalatiojn Phase 1 trial for the treatment ofwet age-relaterd macular degeneration (AMD), a leading causee of blindness in individuals over the age of 50. - Cell Transplantation Therapy for congestiveheart failure.
Each of our product candidates (excluding Cell Transplantation were discovered usingour patent-protected gene delivery technologu platform to deliver gene that produce medically beneficial proteins at the site of ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment